{
    "clinical_study": {
        "@rank": "65", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the induction of durable remission in patients with life-threatening systemic\n      lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide.\n\n      II. Determine the toxicity of this drug in these patients."
        }, 
        "brief_title": "Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome", 
        "condition": [
            "Systemic Lupus Erythematosus", 
            "Antiphospholipid Antibody Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lupus Erythematosus, Systemic", 
                "Antiphospholipid Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10\n      and continuing until blood counts recover.\n\n      Patients are followed monthly for 6 months, and then every 3 months thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of life-threatening systemic lupus erythematosus (SLE); must show at least 4\n        American College of Rheumatology criteria for SLE; must have severe organ damage in 1 or\n        more organs; must have 1 or more of the following indications of ongoing disease activity:\n        disease activity score (SLEDAI) at least 4, hospitalization for disease activity within 12\n        months, life-threatening disease not captured on SLEDAI\n\n        OR\n\n        Diagnosis of antiphospholipid antibody syndrome by the Hughes criteria; must show severity\n        by ongoing symptoms or signs of hypercoagulability in spite of warfarin therapy\n\n        --Patient Characteristics--\n\n        Hepatic: Bilirubin no greater than 2.0 mg/dL; transaminases no greater than 2.0 times\n        normal\n\n        Renal: Creatinine no greater than 3.0 mg/dL\n\n        Cardiovascular: Ejection fraction at least 45%\n\n        Pulmonary: FVC, FEV1, or DLCO at least 50% predicted\n\n        Other: Not preterminal or moribund; not pregnant or nursing; fertile patients must use\n        effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "35", 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010400", 
            "org_study_id": "199/15673", 
            "secondary_id": [
                "JHOC-J9717", 
                "JHOC-97022128"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Antibodies, Antiphospholipid", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "antiphospholipid antibody syndrome", 
            "arthritis & connective tissue diseases", 
            "immunologic disorders and infectious disorders", 
            "rare disease", 
            "systemic lupus erythematosus"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Robert A. Brodsky", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010400"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 1997", 
        "study_design": "Allocation: Non-Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {
        "Johns Hopkins Oncology Center": "39.29 -76.612", 
        "Johns Hopkins University School of Medicine": "39.29 -76.612"
    }
}